{"id":"non-lipid-artificial-tear","safety":{"commonSideEffects":[{"rate":null,"effect":"Ocular irritation"},{"rate":null,"effect":"Transient blurred vision"},{"rate":null,"effect":"Eye discomfort"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This artificial tear product is designed to provide ocular surface lubrication and protection for dry eye disease by delivering aqueous and mucin-like components without lipid-based ingredients. Non-lipid formulations may reduce irritation in certain patient populations and provide sustained hydration of the cornea and conjunctiva. The product aims to restore tear film stability and reduce symptoms associated with dry eye syndrome.","oneSentence":"A non-lipid artificial tear formulation that lubricates and protects the ocular surface by mimicking natural tear composition without lipid components.","_ai_confidence":"low"},"_scrapedAt":"2026-03-27T23:35:05.690Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Dry eye disease / Keratoconjunctivitis sicca"}]},"trialDetails":[{"nctId":"NCT07408297","phase":"PHASE2","title":"Evaluating Safety and Immune Response of Janssen, Moderna, Pfizer/BNT, and Novavax COVID-19 Vaccines for Same and Mixed Boosters in Adolescents and Adults Aged 12-64 With and Without HIV in Kenya, DRC, and Rwanda","status":"COMPLETED","sponsor":"Victoria Biomedical Research Institute","startDate":"2022-05-18","conditions":"COVID -19, SARS CoV 2 Infection","enrollment":1919},{"nctId":"NCT05737342","phase":"NA","title":"Effect of ANKASCIN 568-P Products on Decreasing HbA1c and Regulating Blood Glucose","status":"RECRUITING","sponsor":"SunWay Biotech Co., LTD.","startDate":"2023-04-01","conditions":"High Blood Sugar, Metabolic Syndrome","enrollment":80},{"nctId":"NCT05737355","phase":"NA","title":"Effect of ANKASCIN 568-P Products Regulating Blood Lipid","status":"RECRUITING","sponsor":"SunWay Biotech Co., LTD.","startDate":"2023-04-01","conditions":"Hyperlipidemias","enrollment":80},{"nctId":"NCT05705518","phase":"PHASE4","title":"Artificial Tears, Tear Lipids and Tear Film Dynamics","status":"COMPLETED","sponsor":"University of California, Berkeley","startDate":"2023-01-30","conditions":"Dry Eye","enrollment":81},{"nctId":"NCT06784661","phase":"PHASE4","title":"Immediate Effects of Lipid-Based and Non-Lipid Artificial Tears on Corneal Aberrations","status":"NOT_YET_RECRUITING","sponsor":"University of Seville","startDate":"2025-02-01","conditions":"Aberration, Corneal Wavefront","enrollment":40},{"nctId":"NCT04492072","phase":"NA","title":"Misoprostol With Mechanical Dilation Versus Oxytocin With Mechanical Dilation for High-risk Pregnancy Inductions","status":"COMPLETED","sponsor":"Thomas Jefferson University","startDate":"2020-08-17","conditions":"Cesarean Section, Misoprostol, Oxytocin","enrollment":150},{"nctId":"NCT02596828","phase":"PHASE2","title":"Prospective Pilot Trial to Assess a Multimodal Molecular Targeted Therapy in Children, Adolescent and Young Adults With Relapsed or Refractory High-grade Pineoblastoma","status":"COMPLETED","sponsor":"University of Regensburg","startDate":"2016-04","conditions":"Pineoblastoma","enrollment":4},{"nctId":"NCT01467986","phase":"PHASE2","title":"Multimodal Molecular Targeted Therapy to Treat Relapsed or Refractory High-risk Neuroblastoma","status":"COMPLETED","sponsor":"University of Regensburg","startDate":"2013-08","conditions":"Neuroblastoma Recurrent","enrollment":130},{"nctId":"NCT03706443","phase":"NA","title":"Tear Lipid Layer Thickness Changes With Use of Emollient and Non-Emollient Eye Drops","status":"COMPLETED","sponsor":"Ohio State University","startDate":"2018-12-05","conditions":"Dry Eye Syndromes, Keratoconjunctivitis Sicca, Lacrimal Apparatus Diseases","enrollment":24},{"nctId":"NCT02956083","phase":"NA","title":"The Effect of Tear Supplements on Contact Lens Comfort","status":"COMPLETED","sponsor":"University of the Incarnate Word","startDate":"2014-07","conditions":"Dry Eye Syndromes, Meibomian Gland Dysfunction","enrollment":30},{"nctId":"NCT01801410","phase":"PHASE3","title":"Induction With Foley OR Misoprostol (INFORM) Study","status":"COMPLETED","sponsor":"University of Liverpool","startDate":"2013-12","conditions":"Pre-eclampsia, Fetus or Newborn; Effects of Induction of Labor","enrollment":602}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":5,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Non-Lipid Artificial Tear","genericName":"Non-Lipid Artificial Tear","companyName":"University of Seville","companyId":"university-of-seville","modality":"Small molecule","firstApprovalDate":"","aiSummary":"A non-lipid artificial tear formulation that lubricates and protects the ocular surface by mimicking natural tear composition without lipid components. Used for Dry eye disease, Ocular surface lubrication and protection.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}